Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 209

1.

Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?

Falk RH.

Eur Heart J. 2019 Jan 18. doi: 10.1093/eurheartj/ehy697. [Epub ahead of print] No abstract available.

PMID:
30668704
2.

High sensitivity M-protein detection in a case of light-chain cardiac amyloidosis without evidence of plasma cell dyscrasia.

Saadalla AM, Singh A, Barnidge D, Kohlhagen M, Merlini G, Falk RH, Murray D.

Am J Hematol. 2018 Dec 21. doi: 10.1002/ajh.25383. [Epub ahead of print] No abstract available.

PMID:
30575105
3.

Relative Apical Sparing of Myocardial Longitudinal Strain Is Explained by Regional Differences in Total Amyloid Mass Rather Than the Proportion of Amyloid Deposits.

Bravo PE, Fujikura K, Kijewski MF, Jerosch-Herold M, Jacob S, El-Sady MS, Sticka W, Dubey S, Belanger A, Park MA, Di Carli MF, Kwong RY, Falk RH, Dorbala S.

JACC Cardiovasc Imaging. 2018 Aug 15. pii: S1936-878X(18)30546-1. doi: 10.1016/j.jcmg.2018.06.016. [Epub ahead of print]

PMID:
30121266
4.

Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis.

Alexander KM, Orav J, Singh A, Jacob SA, Menon A, Padera RF, Kijewski MF, Liao R, Di Carli MF, Laubach JP, Falk RH, Dorbala S.

JAMA Cardiol. 2018 Sep 1;3(9):865-870. doi: 10.1001/jamacardio.2018.2093.

PMID:
30046835
5.

True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis.

Singh A, Geller HI, Alexander KM, Padera RF, Mitchell RN, Dorbala S, Castillo JJ, Falk RH.

Haematologica. 2018 Aug;103(8):e374-e376. doi: 10.3324/haematol.2018.190405. Epub 2018 Apr 19. No abstract available.

6.

'A new staging system for cardiac transthyretin amyloidosis': is it already on the verge of obsolescence?

Singh A, Falk RH.

Eur Heart J. 2018 Aug 7;39(30):2807-2809. doi: 10.1093/eurheartj/ehx740. No abstract available.

PMID:
29351628
7.

Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis.

Geller HI, Singh A, Mirto TM, Padera R, Mitchell R, Laubach JP, Falk RH.

Mayo Clin Proc. 2017 Dec;92(12):1800-1805. doi: 10.1016/j.mayocp.2017.09.016.

PMID:
29202938
8.
9.

Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis.

Geller HI, Singh A, Alexander KM, Mirto TM, Falk RH.

JAMA. 2017 Sep 12;318(10):962-963. doi: 10.1001/jama.2017.9236. No abstract available.

10.

Novel pharmacotherapies for cardiac amyloidosis.

Alexander KM, Singh A, Falk RH.

Pharmacol Ther. 2017 Dec;180:129-138. doi: 10.1016/j.pharmthera.2017.06.011. Epub 2017 Jun 22. Review.

11.

Left atrial structure and function in cardiac amyloidosis.

Nochioka K, Quarta CC, Claggett B, Roca GQ, Rapezzi C, Falk RH, Solomon SD.

Eur Heart J Cardiovasc Imaging. 2017 Oct 1;18(10):1128-1137. doi: 10.1093/ehjci/jex097.

PMID:
28637305
12.

Val122Ile mt-ATTR Has a Worse Survival Than wt-ATTR Cardiac Amyloidosis.

Singh A, Geller HI, Falk RH.

J Am Coll Cardiol. 2017 Feb 14;69(6):757-758. doi: 10.1016/j.jacc.2016.09.987. No abstract available.

13.

Role of Imaging in Evaluating Infiltrative Heart Disease.

Divakaran S, Singh A, Collins B, Vita T, Falk RH, Di Carli MF, Blankstein R.

Curr Treat Options Cardiovasc Med. 2017 Jan;19(1):3. doi: 10.1007/s11936-017-0500-3. Review.

14.

A tale of two diagnoses: The role of noninvasive cardiovascular imaging to differentiate cardiac amyloidosis.

Kassop D, Nam JJ, Cebula BR, Shah P, Blankstein R, Falk RH, Hulten EA.

J Nucl Cardiol. 2017 Dec;24(6):2030-2032. doi: 10.1007/s12350-016-0718-6. Epub 2016 Nov 8. No abstract available.

PMID:
27826773
15.

AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy.

Falk RH, Alexander KM, Liao R, Dorbala S.

J Am Coll Cardiol. 2016 Sep 20;68(12):1323-41. doi: 10.1016/j.jacc.2016.06.053. Review.

16.

V122I TTR Cardiac Amyloidosis in Patients of African Descent: Recognizing a Missed Disease or the Dog That Didn't Bark?

Alexander KM, Falk RH.

Circ Heart Fail. 2016 Sep;9(9). pii: e003489. doi: 10.1161/CIRCHEARTFAILURE.116.003489. No abstract available.

PMID:
27618856
17.

Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN.

Circulation. 2016 Jun 14;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612. Epub 2016 Apr 22.

PMID:
27143678
18.

Pondering the Prognosis and Pathology of Cardiac Amyloidosis: Answers Breed Questions.

Falk RH.

JACC Cardiovasc Imaging. 2016 Feb;9(2):139-41. doi: 10.1016/j.jcmg.2015.07.018. Epub 2016 Jan 6. No abstract available.

19.

18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study.

Park MA, Padera RF, Belanger A, Dubey S, Hwang DH, Veeranna V, Falk RH, Di Carli MF, Dorbala S.

Circ Cardiovasc Imaging. 2015 Aug;8(8). pii: e002954. doi: 10.1161/CIRCIMAGING.114.002954.

20.

Characterization of Cardiac Amyloidosis by Atrial Late Gadolinium Enhancement Using Contrast-Enhanced Cardiac Magnetic Resonance Imaging and Correlation With Left Atrial Conduit and Contractile Function.

Kwong RY, Heydari B, Abbasi S, Steel K, Al-Mallah M, Wu H, Falk RH.

Am J Cardiol. 2015 Aug 15;116(4):622-9. doi: 10.1016/j.amjcard.2015.05.021. Epub 2015 May 22.

21.

Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity.

Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, Shirihai OS, Connors LH, Seldin DC, Falk RH, MacRae CA, Liao R.

EMBO Mol Med. 2015 May;7(5):688. doi: 10.15252/emmm.201505318. No abstract available.

22.

V122I transthyretin variant in elderly black Americans.

Quarta CC, Falk RH, Solomon SD.

N Engl J Med. 2015 Apr 30;372(18):1769. doi: 10.1056/NEJMc1503222. No abstract available.

PMID:
25923562
23.

Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.

Maurer MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I, Quyyumi AA, Aarts J, Falk RH.

Circ Heart Fail. 2015 May;8(3):519-26. doi: 10.1161/CIRCHEARTFAILURE.113.000890. Epub 2015 Apr 14.

PMID:
25872787
24.

Echocardiography in cardiac amyloidosis.

Falk RH, Quarta CC.

Heart Fail Rev. 2015 Mar;20(2):125-31. doi: 10.1007/s10741-014-9466-3. Review.

PMID:
25597027
25.

The amyloidogenic V122I transthyretin variant in elderly black Americans.

Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, Mosley TH, Butler KR, Boerwinkle E, Solomon SD.

N Engl J Med. 2015 Jan 1;372(1):21-9. doi: 10.1056/NEJMoa1404852.

26.

Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity.

Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, Shirihai OS, Connors LH, Seldin DC, Falk RH, MacRae CA, Liao R.

EMBO Mol Med. 2014 Nov;6(11):1493-507. doi: 10.15252/emmm.201404190. Erratum in: EMBO Mol Med. 2015 May;7(5):688.

27.

"Bendopnea" or "kamptopnea?": Some thoughts on terminology and mechanisms.

Falk RH.

JACC Heart Fail. 2014 Aug;2(4):425. doi: 10.1016/j.jchf.2014.03.011. No abstract available.

28.

How to image cardiac amyloidosis.

Falk RH, Quarta CC, Dorbala S.

Circ Cardiovasc Imaging. 2014 May;7(3):552-62. doi: 10.1161/CIRCIMAGING.113.001396. No abstract available.

29.

Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography.

Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr, Di Carli MF, Moore SC, Falk RH.

Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1652-62. doi: 10.1007/s00259-014-2787-6. Epub 2014 May 20.

PMID:
24841414
30.

Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.

Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, Gagliardi C, Milandri A, Rapezzi C, Falk RH.

Circulation. 2014 May 6;129(18):1840-9. doi: 10.1161/CIRCULATIONAHA.113.006242. Epub 2014 Feb 21.

PMID:
24563469
31.

AL amyloidosis or multiple myeloma? An important distinction.

Falk RH.

Br J Haematol. 2014 Mar;164(5):748-9. doi: 10.1111/bjh.12677. Epub 2013 Nov 22. No abstract available.

PMID:
24261595
32.

Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity.

Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X, Gianni D, Jiang B, Del Monte F, Connors LH, Seldin DC, Lavatelli F, Rognoni P, Palladini G, Merlini G, Falk RH, Semigran MJ, Dec GW Jr, Macrae CA, Liao R.

Basic Res Cardiol. 2013 Sep;108(5):378. doi: 10.1007/s00395-013-0378-5. Epub 2013 Aug 28.

33.

Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.

Mishra S, Guan J, Plovie E, Seldin DC, Connors LH, Merlini G, Falk RH, MacRae CA, Liao R.

Am J Physiol Heart Circ Physiol. 2013 Jul 1;305(1):H95-103. doi: 10.1152/ajpheart.00186.2013. Epub 2013 Apr 26.

34.

A transthyretin variant, Asp18Asn, associated with amyloid cardiomyopathy: a new African-American variant?

Quarta CC, Falk RH.

Amyloid. 2012 Dec;19(4):204-7. doi: 10.3109/13506129.2012.736890.

PMID:
23126592
35.

Cardiac amyloidosis.

Quarta CC, Kruger JL, Falk RH.

Circulation. 2012 Sep 18;126(12):e178-82. doi: 10.1161/CIRCULATIONAHA.111.069195. No abstract available.

PMID:
22988049
36.

Quantification of extracellular matrix expansion by CMR in infiltrative heart disease.

Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY.

JACC Cardiovasc Imaging. 2012 Sep;5(9):897-907. doi: 10.1016/j.jcmg.2012.04.006.

37.

Longitudinal strain imaging in light-chain cardiac amyloidosis: can it help to refine the approach to treatment?

Quarta CC, Falk RH.

J Am Coll Cardiol. 2012 Sep 18;60(12):1077-8. doi: 10.1016/j.jacc.2012.06.007. Epub 2012 Aug 8. No abstract available.

38.

Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).

Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR.

Am Heart J. 2012 Aug;164(2):222-228.e1. doi: 10.1016/j.ahj.2012.04.015.

PMID:
22877808
39.

Senile systemic amyloidosis: are regional differences real or do they reflect different diagnostic suspicion and use of techniques?

Falk RH.

Amyloid. 2012 Jun;19 Suppl 1:68-70. doi: 10.3109/13506129.2012.674074. Review.

PMID:
22620969
40.

Cardiac amyloidosis mimicking hypertrophic cardiomyopathy with obstruction: treatment with disopyramide.

Philippakis AA, Falk RH.

Circulation. 2012 Apr 10;125(14):1821-4. doi: 10.1161/CIRCULATIONAHA.111.064246. No abstract available.

PMID:
22492950
41.

Dronedarone in high-risk permanent atrial fibrillation.

Falk RH.

N Engl J Med. 2012 Mar 22;366(12):1159-60; author reply 1161. doi: 10.1056/NEJMc1200742. No abstract available.

PMID:
22435379
42.

Hidradenitis suppurativa resulting in systemic amyloid A amyloidosis: a case report and review of the literature.

Girouard SD, Falk RH, Rennke HG, Merola JF.

Dermatol Online J. 2012 Jan 15;18(1):2. Review.

PMID:
22301039
43.

Letter by Falk regarding article, "An unusual heart failure: cardiac amyloidosis due to light chain myeloma".

Falk RH.

Circulation. 2011 Nov 15;124(20):e534; author reply e535. doi: 10.1161/CIRCULATIONAHA.111.046953. No abstract available.

PMID:
22083153
44.

Current perspectives on cardiac amyloidosis.

Guan J, Mishra S, Falk RH, Liao R.

Am J Physiol Heart Circ Physiol. 2012 Feb 1;302(3):H544-52. doi: 10.1152/ajpheart.00815.2011. Epub 2011 Nov 4. Review.

45.

Cardiac amyloidosis: a treatable disease, often overlooked.

Falk RH.

Circulation. 2011 Aug 30;124(9):1079-85. doi: 10.1161/CIRCULATIONAHA.110.010447. No abstract available.

PMID:
21875922
46.

Myxoma, dyspnoea, tinnitus, scoliosis, and alopecia.

Rajab TK, Shekar P, Falk RH.

Lancet. 2011 Apr 16;377(9774):1378. doi: 10.1016/S0140-6736(11)60328-0. No abstract available.

PMID:
21497702
47.

Pulmonary venous isolation for atrial fibrillation in severe systolic heart failure: more questions than answers?

Falk RH.

Heart. 2011 May;97(9):687-8. doi: 10.1136/hrt.2010.214866. Epub 2011 Jan 30. No abstract available.

PMID:
21282135
48.

Pursuing an underdiagnosed disease: a simple imaging test for increasing suspicion of cardiac amyloidosis.

Falk RH, Dorbala S.

Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):467-9. doi: 10.1007/s00259-011-1727-y. No abstract available.

PMID:
21267559
49.

Amyloid diseases of the heart: assessment, diagnosis, and referral.

Dubrey SW, Hawkins PN, Falk RH.

Heart. 2011 Jan;97(1):75-84. doi: 10.1136/hrt.2009.190405. Review. No abstract available.

PMID:
21148582
50.

Clinical problem-solving. A heavy heart.

Miller AL, Falk RH, Levy BD, Loscalzo J.

N Engl J Med. 2010 Oct 7;363(15):1464-9. doi: 10.1056/NEJMcps0804916. No abstract available.

PMID:
20925549

Supplemental Content

Support Center